Transcendental Meditation in Veterans and First Responders With PTSD

NCT ID: NCT05645042

Last Updated: 2025-04-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-12

Study Completion Date

2024-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study is part of a Phase 3 multi-site clinical trial that will recruit veterans and first responders diagnosed with PTSD, where they will be randomized to receive either Transcendental Meditation (TM) or Present Centered Therapy (PCT). Five assessments will be conducted, at: 1) baseline, 2) midpoint, 3) posttreatment, 4) three months posttreatment and 5) six months posttreatment. All assessments will be completed using remote HIPAA-compliant videoconferencing. The study protocol at NYSPI/Columbia will also include Magnetic Resonance Imaging (MRI) before and after treatment to elucidate neural predictors and mechanisms of these two treatment approaches.

Enrollment will include veterans and first responders with PTSD. Both TM and PCT will be provided by trained staff receiving weekly supervision. This trial is funded by the David Lynch Foundation and will recruit approximately 360 veterans and first responders over a three-year period.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PTSD is among the most common and disabling problems for veterans and first responders. Although PTSD from combat-related events is widely known, veterans and first-responders also face traumatic experiences from other events including sexual trauma, accidents, and injuries. Recent findings, for example, indicated that nearly a quarter of female Veterans experienced sexual assault when in the military.

At present, the non-medication therapies for PTSD with the strongest scientific support include Prolonged Exposure (PE), Cognitive Processing Therapy (CPT), and Eye Movement Desensitization and Reprocessing (EMDR). While many patients with PTSD benefit from these therapies, research indicates that these psychotherapies appear to be less effective for veterans than for civilians with PTSD, and many veterans may remained symptomatic in the long run. Based on this evidence, there is a clear need for new PTSD treatments that are effective for and amenable to the unique circumstances of veterans and first-responders.

Transcendental Meditation (TM) is a promising intervention. A phase 2 clinical trial, funded by the Department of Defense and conducted at the San Diego VA, showed that TM significantly reduces both PTSD symptom severity and depression in a veteran population, with post-hoc analysis indicating reduced suicidal ideation. Relative to conventional PTSD treatments that aim to improve symptoms through mechanisms such as habituation to anxiety-provoking stimuli and desensitization to trauma-related memories, TM improves symptoms by aiming to calm down the nervous system.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PTSD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Transcendental Meditation (TM):

TM treatment for PTSD is designed to reduce stress, facilitate deep rest, and increase well-being. It was originally conceptualized as an effortless technique to enable physical relaxation. The treatment will be delivered by experienced, certified TM instructors receiving weekly supervision.

Group Type ACTIVE_COMPARATOR

Transcendental Meditation (TM)

Intervention Type BEHAVIORAL

During the first week, each participant randomized to undergo TM will meet with a TM instructor on four consecutive days for 60 minutes, for an introductory training. Next, participants will meet for twelve 60-minute sessions over the course of three months and then once monthly for booster sessions for 6 months. All sessions will be recorded and reviewed for adherence to the TM protocol.

Present Centered Therapy (PCT):

PCT is a focused time-limited treatment for PTSD that focuses on increasing adaptive responses to current life stressors and difficulties that are directly or indirectly related to trauma or PTSD symptoms. PCT was originally designed as a treatment comparator in trials evaluating the effectiveness of trauma-focused cognitive-behavioral therapies such as PE and CPT. Several clinical trials have indicated that PCT may be an effective treatment option for PTSD and that patients may drop out of PCT at lower rates relative to trauma focused forms of CBT.

Group Type ACTIVE_COMPARATOR

Present Centered Therapy (PCT)

Intervention Type BEHAVIORAL

PCT treatments will be delivered by trained clinicians at master's or doctoral-level. Study therapists will be supervised by a a licensed psychologist. Participants assigned to this treatment will meet with a PCT therapist once a week for twelve 60-minute sessions over the course of 3 months and then monthly for months four through nine. Sessions will focus on current life problems as manifestations of PTSD. All sessions will be recorded and reviewed for adherence to the treatment protocol.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transcendental Meditation (TM)

During the first week, each participant randomized to undergo TM will meet with a TM instructor on four consecutive days for 60 minutes, for an introductory training. Next, participants will meet for twelve 60-minute sessions over the course of three months and then once monthly for booster sessions for 6 months. All sessions will be recorded and reviewed for adherence to the TM protocol.

Intervention Type BEHAVIORAL

Present Centered Therapy (PCT)

PCT treatments will be delivered by trained clinicians at master's or doctoral-level. Study therapists will be supervised by a a licensed psychologist. Participants assigned to this treatment will meet with a PCT therapist once a week for twelve 60-minute sessions over the course of 3 months and then monthly for months four through nine. Sessions will focus on current life problems as manifestations of PTSD. All sessions will be recorded and reviewed for adherence to the treatment protocol.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Prior or current military service OR prior or current work as a first responder (law enforcement, firefighters, and EMS)
2. Active and primary diagnosis of PTSD with symptom duration ≥ 3 months
3. CAPS-5 score ≥ 25 at intake assessment
4. Age 18 - 80
5. Able to give consent, English literate


1. Prior or current military service OR prior or current work as a first responder (law enforcement, firefighters, and/or EMS)
2. Active and primary diagnosis of PTSD with symptom duration ≥ 3 months
3. CAPS-5 score ≥ 25 at intake assessment
4. Age 18 - 80
5. Able to give consent, English literate
6. Right handed

Exclusion Criteria

1. Previous or current treatment with Transcendental Meditation, Present Centered Therapy, or any current psychotherapy.
2. Current severe alcohol/cannabis use disorder or any other current substance use disorder except nicotine (i.e., nicotine use disorder and mild-moderate alcohol/cannabis use disorder are allowed)
3. History of or present psychiatric diagnosis of psychotic episode, psychotic disorder, schizophrenia, schizoaffective disorder
4. Current diagnosis of bipolar disorder
5. Active suicidal or homicidal ideation or suicide attempt within two years of study enrollment
6. Psychiatric hospitalization in the past six months
7. Intent to change or begin new psychotherapy or other meditation therapy during 3-month study treatment
8. Intent to enroll in another research study testing an experimental intervention during three-month period of study intervention
9. Recent psychotropic medication dosage change or initiation within the three months prior to study enrollment
10. Intent to change dosage of or initiate new psychotropic medication during the three-month period of study intervention
11. Medical illness that could interfere with assessment of diagnosis, such as organic brain impairment or unstable thyroid disease
12. Current unstable medical illness


1. Previous or current treatment with Transcendental Meditation, Present Centered Therapy, or any current psychotherapy.
2. Current severe alcohol/cannabis use disorder or any other current substance use disorder except nicotine (i.e., nicotine use disorder and mild-moderate alcohol/cannabis use disorder are allowed)
3. History of or current psychiatric diagnosis of psychotic episode, psychotic disorder, schizophrenia, schizoaffective disorder
4. Current diagnosis of bipolar disorder
5. Active suicidal or homicidal ideation or suicide attempt within two years of study enrollment
6. Psychiatric hospitalization in the past six months
7. Intent to change or begin new psychotherapy or other meditation therapy during 3-month study intervention
8. Intent to enroll in another research study testing an experimental intervention during three-month period of study intervention
9. Recent psychotropic medication dosage change or initiation within the three months prior to study enrollment
10. Intent to change dosage of or initiate new psychotropic medication during the three-month period of study intervention
11. Paramagnetic metallic implants or devices contraindicating magnetic resonance imaging or any other non-removable paramagnetic metal in the body.
12. Medical illness that could interfere with assessment of diagnosis, such as organic brain impairment or unstable thyroid disease
13. Current unstable medical illness
14. Any condition that would exclude clinical MRI exam (e.g. pacemaker, paramagnetic metallic prosthesis, surgical clips, shrapnel, necessity for constant medicinal patch, some tattoos)
15. Significant claustrophobia that would preclude ability to remain calm within the MRI scanner
16. Females who are pregnant or breastfeeding, or plan to become pregnant during the period of the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Columbia University

OTHER

Sponsor Role collaborator

Northwell Health

OTHER

Sponsor Role collaborator

Brown University

OTHER

Sponsor Role collaborator

University of California, San Diego

OTHER

Sponsor Role collaborator

University of Southern California

OTHER

Sponsor Role collaborator

VA Palo Alto Health Care System

FED

Sponsor Role collaborator

New York State Psychiatric Institute

OTHER

Sponsor Role collaborator

Icahn School of Medicine at Mount Sinai

OTHER

Sponsor Role collaborator

Research Foundation for Mental Hygiene, Inc.

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yuval Y Neria

Professor of Medical Psychology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yuval Neria, PhD

Role: PRINCIPAL_INVESTIGATOR

NYSPI and Columbia University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California San Diego

La Jolla, California, United States

Site Status

University of Southern California

Los Angeles, California, United States

Site Status

Stanford University

Palo Alto, California, United States

Site Status

Northwell Health

Great Neck, New York, United States

Site Status

New York State Psychiatric Institute

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Nidich S, Mills PJ, Rainforth M, Heppner P, Schneider RH, Rosenthal NE, Salerno J, Gaylord-King C, Rutledge T. Non-trauma-focused meditation versus exposure therapy in veterans with post-traumatic stress disorder: a randomised controlled trial. Lancet Psychiatry. 2018 Dec;5(12):975-986. doi: 10.1016/S2215-0366(18)30384-5. Epub 2018 Nov 15.

Reference Type BACKGROUND
PMID: 30449712 (View on PubMed)

Belsher BE, Beech E, Evatt D, Smolenski DJ, Shea MT, Otto JL, Rosen CS, Schnurr PP. Present-centered therapy (PCT) for post-traumatic stress disorder (PTSD) in adults. Cochrane Database Syst Rev. 2019 Nov 18;2019(11):CD012898. doi: 10.1002/14651858.CD012898.pub2.

Reference Type BACKGROUND
PMID: 31742672 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

8172

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Big Mind for Veterans With PTSD
NCT02541630 WITHDRAWN NA
TMS for PTSD and Blood Pressure
NCT05512143 ACTIVE_NOT_RECRUITING NA
Ultrasonic Neuromodulation for Treatment of PTSD
NCT06135064 TERMINATED PHASE1/PHASE2